| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,110,000 |
| Market
Cap: |
3.51(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.73 - $53.69 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
69,133 |
99,133 |
200,384 |
249,340 |
| Total Sell Value |
$3,373,178 |
$4,809,278 |
$8,291,909 |
$10,478,837 |
| Total People Sold |
8 |
8 |
9 |
12 |
| Total Sell Transactions |
10 |
11 |
20 |
34 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Huang Dennis Karl |
See Remarks |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
24,663 |
75,703 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2023-02-28 |
4 |
AS |
$43.40 |
$27,733 |
D/D |
(639) |
15,558 |
|
-1% |
|
| Kakkis Emil D |
President & CEO |
• • – |
2022-12-30 |
4 |
AS |
$45.57 |
$892,352 |
D/D |
(19,582) |
541,108 |
|
2% |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2022-12-21 |
4 |
AS |
$43.96 |
$89,283 |
D/D |
(2,031) |
16,197 |
|
-2% |
|
| Dier Mardi |
CFO & Executive Vice President |
• – – |
2022-10-14 |
4 |
AS |
$40.16 |
$65,421 |
D/D |
(1,629) |
66,695 |
|
20% |
|
| Dier Mardi |
CFO & Executive Vice President |
• – – |
2022-10-12 |
4 |
S |
$38.22 |
$133,158 |
D/D |
(3,484) |
68,324 |
|
-14% |
|
| Dier Mardi |
CFO & Executive Vice President |
• – – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
71,808 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2022-09-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
18,094 |
|
- |
|
| Sanders Corazon (corsee) D. |
Director |
– • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
7,195 |
|
- |
|
| Narachi Michael |
Director |
– • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
17,745 |
|
- |
|
| Ekman Lars |
Director |
– • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
17,745 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
17,745 |
|
- |
|
| Dunsire Deborah |
Director |
– • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
15,870 |
|
- |
|
| Ray Amrit |
Director |
– • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
8,420 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
26,495 |
|
- |
|
| Suliman Shehnaaz |
Director |
– • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
10,995 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2022-06-19 |
4 |
S |
$54.78 |
$16,160 |
D/D |
(295) |
36,160 |
|
27% |
|
| Ray Amrit |
Director |
– • – |
2022-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,120 |
5,120 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2022-04-16 |
4 |
S |
$84.55 |
$11,161 |
D/D |
(132) |
16,914 |
|
37% |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2022-03-11 |
4 |
S |
$67.01 |
$688,930 |
D/D |
(10,281) |
227,559 |
|
17% |
|
| Parschauer Karah Herdman |
EVP and Chief Legal Officer |
• – – |
2022-03-07 |
4 |
S |
$62.95 |
$323,563 |
D/D |
(5,140) |
34,438 |
|
-3% |
|
| Fust Matthew K |
Director |
– • – |
2022-03-04 |
4 |
OE |
$40.37 |
$302,775 |
D/D |
7,500 |
23,195 |
|
- |
|
| Dier Mardi |
CFO & Executive Vice President |
• – – |
2022-03-03 |
4 |
AS |
$64.55 |
$27,111 |
D/D |
(420) |
51,808 |
|
3% |
|
| Kakkis Emil D |
President & CEO |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
52,041 |
634,226 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2022-03-01 |
4 |
D |
$67.37 |
$819,354 |
D/D |
(12,162) |
582,185 |
|
- |
|
628 Records found
|
|
Page 4 of 26 |
|
|
0.45 (1.04%) 
